Grant: Project Grant
McGill University
$669,376.00
An integrative approach for biotechnological production of next-generation anticancer agents
EF 2021-22
Résumé
Taxol is one of the best anticancer drugs ever developed, used against ovarian, breast, lung and other cancers. Its effectiveness combined with anticipated further therapeutic applications has generated huge demand for the drug, which outpace current supply. Yet, an inexpensive taxol production method is lacking, raising the cost of treatment for one patient to $7000 for 6 cycles of chemotherapy. Taxol extraction from natural sources demands destruction of two adult yew trees to obtain 1 g of compound. Chemical synthesis is very complicated and inefficient, hence not suitable for industrial scale. A sustainable and economical solution is production of taxol in simple organisms, such as yeast. For this purpose, the entire enzymatic route of taxol formation that naturally occurs in plants must be transplanted in yeast. However, not all enzymes involved in taxol biosynthesis are known and how they work together along the 19 steps is yet unclear. We will use synthetic biology, computational science and analytical and organic chemistry to develop high throughput approaches for engineering yeast cells to produce complex taxol intermediate compounds, which could be further chemically modified to taxol or other promising analogs. This will be achieved by discovery and clarification of yet unknown or ambiguous reactions. Subsequently, we will introduce in the system pathway-unrelated enzymes to enable new modifications of the taxol natural skeleton and synthesis of novel compounds. Following optimization of precursors, pathway balancing and establishment of optimal culture parameters, we expect to obtain increased yields of intermediate compounds of interest for bioactivity assays and future applications and benefit cancer patients.
Programme
Project Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
463073
Name
Ignea Codruta
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Tri-Agency Interdisciplinary - CIHR TIR
Projecttitle
An integrative approach for biotechnological production of next-generation anticancer agents
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$669,376
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Gene Mining; Metabolic Engineering; Metabolic Pathways; Protein Engineering; Specilized Metabolism; Synthetic Biology; Terpenoids; Yeast Cell Factory
Abstract
Taxol is one of the best anticancer drugs ever developed, used against ovarian, breast, lung and other cancers. Its effectiveness combined with anticipated further therapeutic applications has generated huge demand for the drug, which outpace current supply. Yet, an inexpensive taxol production method is lacking, raising the cost of treatment for one patient to $7000 for 6 cycles of chemotherapy. Taxol extraction from natural sources demands destruction of two adult yew trees to obtain 1 g of compound. Chemical synthesis is very complicated and inefficient, hence not suitable for industrial scale. A sustainable and economical solution is production of taxol in simple organisms, such as yeast. For this purpose, the entire enzymatic route of taxol formation that naturally occurs in plants must be transplanted in yeast. However, not all enzymes involved in taxol biosynthesis are known and how they work together along the 19 steps is yet unclear. We will use synthetic biology, computational science and analytical and organic chemistry to develop high throughput approaches for engineering yeast cells to produce complex taxol intermediate compounds, which could be further chemically modified to taxol or other promising analogs. This will be achieved by discovery and clarification of yet unknown or ambiguous reactions. Subsequently, we will introduce in the system pathway-unrelated enzymes to enable new modifications of the taxol natural skeleton and synthesis of novel compounds. Following optimization of precursors, pathway balancing and establishment of optimal culture parameters, we expect to obtain increased yields of intermediate compounds of interest for bioactivity assays and future applications and benefit cancer patients.
Competitiondate
202203
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Ignea, Codruta
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $669,376~ $0~